JJDC
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
TRIMTECH Therapeutics
23 Jun 2026
TRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
TRIMTECH Therapeutics is a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases. Its TRIMTAC and TRIMGLUE platforms are designed to selectively degrade toxic protein aggregates and oligomers whilst leaving functional monomeric forms of those proteins intact to support healthy cellular function.
Mestag Therapeutics
16 Mar 2026
Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies
Mestag Therapeutics develops antibody treatments based on fibroblast immunology for cancer and inflammatory diseases. It is building therapies designed to direct and drive immune responses using fibroblast-immune biology.
JJDC
More venture news
- 10 Aug 2026
EdgifyEdgify raises a £6.7m Series A+ round from Rank Ventures and Mangrove Capital Partners for edge AI that prevents in-store retail loss
ExtensionCommerce - 23 Jul 2026
YopeYope raises a £9.2m Pre-Series A round led by Northzone to build private social platform for close friends
ExtensionConsumer - 21 Jul 2026
Mach42Mach42 raises a £7m pre-Series A round led by IP Group to speed up analog circuit verification for semiconductor engineers
ExtensionDeep Tech
